Core Viewpoint - Shenwei Pharmaceutical (02877) reported a decline in revenue and profit for the first half of 2025, indicating challenges in the market due to rising raw material costs and pricing pressures from centralized procurement [1] Financial Performance - Revenue for the first half of 2025 was 1.653 billion RMB, a decrease of 20.8% year-on-year [1] - Profit for the period was 615 million RMB, down 1.89% compared to the previous year [1] - Basic earnings per share were 0.81 RMB, with an interim dividend proposed at 0.11 RMB per share [1] Profitability Metrics - The group's gross profit margin decreased from 75.3% in the same period last year to 72.2% [1] - Despite the decline in sales and gross margin, net profit only slightly decreased by 1.9%, with the net profit margin increasing from 30.0% to 37.2% [1] Cost Management - The company managed to reduce selling and distribution costs and administrative expenses by approximately 20.7% and 12.9% respectively compared to the previous year [1] - Increased investment income contributed positively to the overall financial performance [1] Product Segment Performance - Oral formulations accounted for 65.8% of total sales in the first half of 2025, while injectable products made up 34.2% [1] - Total sales of injectable products decreased by 27.4% year-on-year, with significant declines in sales for specific products such as Qingkailing and Shenmai injections, which fell by 50.1% and 21.0% respectively [1]
神威药业发布中期业绩 期内溢利6.15亿元 同比减少1.89%